Overall, systemic immunological profiling supports the safety of topical CCL3 therapy in diabetic mice, as treatment did not exacerbate circulating markers, including IgE and CRP which are commonly elevated in diabetes and linked to disease complications [42,65]. This evidence concerns the gene CRP and diabetes mellitus.